A protein kinase is a kinase enzyme that modifies other proteins by chemically adding phosphate groups to them (phosphorylation). Phosphorylation usually results in a functional change of the target protein (substrate) by changing enzyme activity, cellular location, or association with other proteins. The human genome contains about 500 protein kinase genes and they constitute about 2% of all human genes. Protein kinases are also found in bacteria and plants. Up to 30% of all human proteins may be modified by kinase activity, and kinases are known to regulate the majority of cellular pathways, especially those involved in signal transduction.
- 1 Chemical activity
- 2 Regulation
- 3 Structure
- 4 Serine/threonine-specific protein kinases
- 5 Tyrosine-specific protein kinases
- 6 Histidine-specific protein kinases
- 7 Aspartic acid/glutamic acid-specific protein kinases
- 8 Mixed kinases
- 9 Inhibitors
- 10 Kinase assays and profiling
- 11 References
- 12 External links
The chemical activity of a kinase involves removing a phosphate group from ATP and covalently attaching it to one of three amino acids that have a free hydroxyl group. Most kinases act on both serine and threonine, others act on tyrosine, and a number (dual-specificity kinases) act on all three. There are also protein kinases that phosphorylate other amino acids, including histidine kinases that phosphorylate histidine residues.
Because protein kinases have profound effects on a cell, their activity is highly regulated. Kinases are turned on or off by phosphorylation (sometimes by the kinase itself - cis-phosphorylation/autophosphorylation), by binding of activator proteins or inhibitor proteins, or small molecules, or by controlling their location in the cell relative to their substrates.
The catalytic subunits of many protein kinases are highly conserved, and several structures have been solved.
Eukaryotic protein kinases are enzymes that belong to a very extensive family of proteins that share a conserved catalytic core. There are a number of conserved regions in the catalytic domain of protein kinases. In the N-terminal extremity of the catalytic domain there is a glycine-rich stretch of residues in the vicinity of a lysine amino acid, which has been shown to be involved in ATP binding. In the central part of the catalytic domain, there is a conserved aspartic acid, which is important for the catalytic activity of the enzyme.
Serine/threonine-specific protein kinases
Serine/threonine protein kinases (EC 184.108.40.206) phosphorylate the OH group of serine or threonine (which have similar side-chains). Activity of these protein kinases can be regulated by specific events (e.g., DNA damage), as well as numerous chemical signals, including cAMP/cGMP, diacylglycerol, and Ca2+/calmodulin. One very important group of protein kinases are the MAP kinases (acronym from: "mitogen-activated protein kinases"). Important subgroups are the kinases of the ERK subfamily, typically activated by mitogenic signals, and the stress-activated protein kinases JNK and p38. While MAP kinases are serine/threonine-specific, they are activated by combined phosphorylation on serine/threonine and tyrosine residues. Activity of MAP kinases is restricted by a number of protein phosphatases, which remove the phosphate groups that are added to specific serine or threonine residues of the kinase and are required to maintain the kinase in an active conformation. Two major factors influence activity of MAP kinases: a) signals that activate transmembrane receptors (either natural ligands or crosslinking agents) and proteins associated with them (mutations that simulate active state) b) signals that inactivate the phosphatases that restrict a given MAP kinase. Such signals include oxidant stress.
Tyrosine-specific protein kinases
Tyrosine-specific protein kinases (EC 220.127.116.11 and EC 18.104.22.168) phosphorylate tyrosine amino acid residues, and like serine/threonine-specific kinases are used in signal transduction. They act primarily as growth factor receptors and in downstream signaling from growth factors ; some examples:
- Platelet-derived growth factor receptor (PDGFR)
- Epidermal growth factor receptor (EGFR) 
- Insulin receptor and insulin-like growth factor 1 receptor (IGF1R)
- Stem cell factor (SCF) receptor (also called c-kit, see the article on gastrointestinal stromal tumor).
Receptor tyrosine kinases
These kinases consist of a transmembrane receptor with a tyrosine kinase domain protruding into the cytoplasm. They play an important role in regulating cell division, cellular differentiation, and morphogenesis. More than 50 receptor tyrosine kinases are known in mammals.
The extracellular domain serves as the ligand-binding part of the molecule. It can be a separate unit that is attached to the rest of the receptor by a disulfide bond. The same mechanism can be used to bind two receptors together to form a homo- or heterodimer. The transmembrane element is a single α helix. The intracellular or cytoplasmic domain is responsible for the (highly conserved) kinase activity, as well as several regulatory functions.
Ligand binding causes two reactions:
- Dimerization of two monomeric receptor kinases or stabilization of a loose dimer. Many ligands of receptor tyrosine kinases are multivalent. Some tyrosine receptor kinases (e.g., the platelet-derived growth factor receptor) can form heterodimers with other similar but not identical kinases of the same subfamily, allowing a highly varied response to the extracellular signal.
- Trans-autophosphorylation (phosphorylation by the other kinase in the dimer) of the kinase.
The autophosphorylation causes the two subdomains of the intrinsic kinase to shift, opening the kinase domain for ATP binding. In the inactive form, the kinase subdomains are aligned so that ATP cannot reach the catalytic center of the kinase. When several amino acids suitable for phosphorylation are present in the kinase domain (e.g., the insulin-like growth factor receptor), the activity of the kinase can increase with the number of phosphorylated amino acids; in this case, the first phosphorylation is said to be a cis-autophosphorylation, switching the kinase from "off" to "standby".
The active tyrosine kinase phosphorylates specific target proteins, which are often enzymes themselves. An important target is the ras protein signal-transduction chain.
Receptor-associated tyrosine kinases
Tyrosine kinases recruited to a receptor following hormone binding are receptor-associated tyrosine kinases and are involved in a number of signaling cascades, in particular those involved in cytokine signaling (but also others, including growth hormone). One such receptor-associated tyrosine kinase is Janus kinase (JAK), many of whose effects are mediated by STAT proteins. (See JAK-STAT pathway.)
Histidine-specific protein kinases
Histidine kinases are structurally distinct from most other protein kinases and are found mostly in prokaryotes as part of two-component signal transduction mechanisms. A phosphate group from ATP is first added to a histidine residue within the kinase, and later transferred to an aspartate residue on a 'receiver domain' on a different protein, or sometimes on the kinase itself. The aspartyl phosphate residue is then active in signaling.
Histidine kinases are found widely in prokaryotes, as well as in plants, fungi and eukaryotes. The pyruvate dehydrogenase family of kinases in animals is structurally related to histidine kinases, but instead phosphorylate serine residues, and probably do not use a phospho-histidine intermediate.
Aspartic acid/glutamic acid-specific protein kinases
This section needs expansion. You can help by adding to it. (June 2008)
Some kinases have mixed kinase activities. For example, MEK (MAPKK), which is involved in the MAP kinase cascade, is a mixed serine/threonine and tyrosine kinase and, hence, is a dual-specificity kinase.
Deregulated kinase activity is a frequent cause of disease, in particular cancer, wherein kinases regulate many aspects that control cell growth, movement and death. Drugs that inhibit specific kinases are being developed to treat several diseases, and some are currently in clinical use, including Gleevec (imatinib) and Iressa (gefitinib).
Kinase assays and profiling
Drug developments for kinase inhibitors are started from kinase assays, the lead compounds are usually profiled for specificity before moving into further tests. Many profiling services are available from fluorescent-based assays to radioisotope based detections, and competition binding assays.
- Evolution of protein kinase signaling from yeast to man (pdf)
- A review on inhibitors of signal transduction protein kinases as targets for cancer therapy
- Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002). "The protein kinase complement of the human genome". Science. 298 (5600): 1912–1934. doi:10.1126/science.1075762. PMID 12471243.
- Dhanasekaran N, Premkumar Reddy E (September 1998). "Signaling by dual specificity kinases". Oncogene. 17 (11 Reviews): 1447–55. doi:10.1038/sj.onc.1202251. PMID 9779990.
- Besant PG, Tan E, Attwood PV (March 2003). "Mammalian protein histidine kinases". Int. J. Biochem. Cell Biol. 35 (3): 297–309. doi:10.1016/S1357-2725(02)00257-1. PMID 12531242.
- Stout TJ, Foster PG, Matthews DJ (2004). "High-throughput structural biology in drug discovery: protein kinases". Curr. Pharm. Des. 10 (10): 1069–82. doi:10.2174/1381612043452695. PMID 15078142.
- Hanks SK (2003). "Genomic analysis of the eukaryotic protein kinase superfamily: a perspective". Genome Biol. 4 (5): 111. doi:10.1186/gb-2003-4-5-111. PMC 156577. PMID 12734000.
- Hanks SK, Hunter T (May 1995). "Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification". FASEB J. 9 (8): 576–96. PMID 7768349.
- Hunter T (1991). "Protein kinase classification". Meth. Enzymol. 200: 3–37. doi:10.1016/0076-6879(91)00125-G. PMID 1835513.
- Hanks SK, Quinn AM (1991). "Protein kinase catalytic domain sequence database: identification of conserved features of primary structure and classification of family members". Meth. Enzymol. 200: 38–62. doi:10.1016/0076-6879(91)00126-H. PMID 1956325.
- Knighton DR, Zheng JH, Ten Eyck LF, Ashford VA, Xuong NH, Taylor SS, Sowadski JM (July 1991). "Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase". Science. 253 (5018): 407–14. doi:10.1126/science.1862342. PMID 1862342.
- Vlahopoulos S, Zoumpourlis VC. JNK: a key modulator of intracellular signaling. Biochemistry (Mosc). 2004 Aug;69(8):844-54. Review. PMID: 15377263
- Higashiyama S, Iwabuki H, Morimoto C, Hieda M, Inoue H, Matsushita N. Membrane-anchored growth factors, the epidermal growth factor family: beyond receptor ligands. Cancer Sci. 2008 Feb;99(2):214-20. Review. PMID: 18271917
- Carpenter G. The EGF receptor: a nexus for trafficking and signaling. Bioessays. 2000 Aug;22(8):697-707. Review. PMID: 10918300
- Human and mouse protein kinases in UniProt: classification and index
- Kinase.Com: Genomics, evolution and large-scale analysis of protein kinases (non-commercial).
- KinMutBase: A registry of disease-causing mutations in protein kinase domains
- Human kinome by Manning et al.
- KLIFS (Kinase-Ligand Interaction Fingerprints and Structures) Database -- analysis of kinase/inhibitor interactions
- Orientations of C1 domains of protein kinases in membranes
- Orientations of C2 domains of protein kinases in membranes